Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 997 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Necitumumab, Osimertinib, Quality-of-Life Assessment, Questionnaire Administration, Trastuzumab
Biological · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Interventions
lorigerlimab, docetaxel, Prednisone
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older · Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more
Conditions
Head and Neck Cancer
Interventions
gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Crohn's Disease
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 8 more
Conditions
Hemodialysis Complication, Hypotension of Hemodialysis
Interventions
Lanadelumab Injection [Takhzyro], Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Cutaneous Metastases
Interventions
Diphencyprone (DPCP)
Drug
Lead sponsor
Nicholas Gulati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Non-small Cell Lung Cancer
Interventions
Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
77
States / cities
Tucson, Arizona • Springdale, Arkansas • Anaheim, California + 69 more
Conditions
Psoriasis
Interventions
Micellar Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Isometric Exercise and Endogenous Pain Inhibition

NCT03778476
Conditions
Fibromyalgia
Interventions
Isometric Exercise
Other
Lead sponsor
Marquette University
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Changes in Biomarkers Using Prostaglandin Inhibitors

NCT01769625
Conditions
Biomarker Change Linked to Breast Cancer
Interventions
placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Grand Forks, North Dakota
Completed No phase listed Observational Accepts healthy volunteers

Brain Plasticity of Verbal Memory in the Blind

NCT00059189
Conditions
Blindness
Interventions
Magstim Rapid Magnetic Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Hematopoetic Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
Interventions
Sitagliptin
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana • Valhalla, New York
Conditions
Coronary Atherosclerosis
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Endometrial Cancer
Interventions
Dasatinib
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Conditions
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure, Computed Tomography, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers

Inhibitory Control: Effects of Modulation

NCT04247334
Conditions
Young Adults
Interventions
Transcranial direct current stimulation
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 25 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Melanoma
Interventions
Nivolumab, Hydroxychloroquine, Ipilimumab
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
Device · Other
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Interventions
Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
Drug · Device
Lead sponsor
Heart Metabolics Limited
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Stanford, California • Indianapolis, Indiana • Baltimore, Maryland + 7 more
Active, not recruiting Phase 2 Interventional

Renal Mechanism of SGLT2 Inhibition

NCT05507892
Conditions
Type 2 Diabetes, Diabetic Kidney Disease
Interventions
canagliflozin, Aminohippurate Sodium Inj 20%
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Ann Arbor, Michigan
Conditions
Generalized Myasthenia Gravis
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fresno, California + 29 more
Conditions
Gastric Bypass Surgery, Obesity
Interventions
Liquid Meal, Solid Meal
Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Liver Metastases, Non-small Cell Lung Cancer
Interventions
Liver SBRT, Pembrolizumab
Radiation · Drug
Lead sponsor
VA Ann Arbor Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan